Hämatologisch-Onkologische Praxis Eppendorf (hope)

The Hämatologisch-Onkologische Praxis Eppendorf is conducting research on advanced adenocarcinoma of the gastroesophageal junction, aiming to improve first‑line therapy options and assess safety of novel drug combinations.

• Evaluation of a new antibody‑drug conjugate combined with standard chemotherapy
• Investigation of immune checkpoint modulation alongside chemotherapy
• Assessment of progression‑free survival and overall response rates

By focusing on this Digestive System Disease, the site seeks to enhance treatment effectiveness and expand therapeutic choices for patients with unresectable or metastatic gastric and gastroesophageal cancers.

In the field of Neoplasms, the center is evaluating targeted therapy for HR+/HER2‑negative breast cancer, comparing a novel kinase inhibitor combined with hormonal treatment to standard care.

• Comparison of progression‑free survival between experimental and placebo arms
• Subgroup analysis based on genetic alterations in the PI3K/AKT pathway
• Monitoring safety and tolerability of the combination regimen

This research aims to offer more personalized options for patients with locally advanced or metastatic breast cancer, potentially extending disease control and improving quality of life.